House ALS Bill Would Require US FDA ‘Action Plan’ – But Not Conditional Approval

US House of Representatives if moving forward with a bill to respond to advocacy from ALS patients for more attention from FDA. The bill focuses on planning and scientific support, not new pathways.

Washington DC Capitol dome detail with waving american flag
• Source: Shutterstock

FDA would be required to develop and implement a five-year “action plan” to foster development of new treatments for ALS and other rare neurological disorder under a bill that appears primed to move quickly through the House of Representatives.

ACT for ALS directs FDA to publish a five-year action plan within six months of the date of enactment,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet